Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accounts Payables: 2022-2025

Historic Accounts Payables for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $225.6 million.

  • Axsome Therapeutics' Accounts Payables rose 84.68% to $225.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 84.68%. This contributed to the annual value of $148.0 million for FY2024, which is 63.52% up from last year.
  • Per Axsome Therapeutics' latest filing, its Accounts Payables stood at $225.6 million for Q3 2025, which was up 32.02% from $170.9 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Accounts Payables high stood at $225.6 million for Q3 2025, and its period low was $12.6 million during Q1 2022.
  • Over the past 3 years, Axsome Therapeutics' median Accounts Payables value was $116.8 million (recorded in 2024), while the average stood at $118.9 million.
  • Data for Axsome Therapeutics' Accounts Payables shows a peak YoY surged of 366.64% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Accounts Payables (Quarterly) stood at $51.6 million in 2022, then spiked by 75.28% to $90.5 million in 2023, then soared by 63.52% to $148.0 million in 2024, then skyrocketed by 84.68% to $225.6 million in 2025.
  • Its last three reported values are $225.6 million in Q3 2025, $170.9 million for Q2 2025, and $149.2 million during Q1 2025.